Ablation of plasma membrane Ca2+-ATPase isoform 4 prevents development of hypertrophy in a model of hypertrophic cardiomyopathy

Journal of Molecular and Cellular Cardiology

Volumn 77, Issue , 2014, Pages 53-63

  Prasad, Vikram ^a   Lorenz, John N ^a   Lasko, Valerie M ^a   Nieman, Michelle L ^a   Jiang, Min ^a   Gao, Xu ^a   Rubinstein, Jack ^a   Wieczorek, David F ^a   Shull, Gary E ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Diastolic dysfunction; Diastolic properties; Hypertrophic cardiomyopathy; Pathological hypertrophy; PMCA4; Ventricular stiffness

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ALPHA TROPOMYOSIN; ANKYRIN; CALCINEURIN; CALCIUM CHANNEL L TYPE; CARNITINE PALMITOYLTRANSFERASE I; CARNITINE PALMITOYLTRANSFERASE IB; CONNECTIN; GLUCOSE TRANSPORTER 4; PHOSPHOPROTEIN; PROTEIN PMCA4; UNCLASSIFIED DRUG; PLASMA MEMBRANE CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; TPM1 PROTEIN, MOUSE; TROPOMYOSIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MEMBRANE; COL1A1 GENE; COL3A1 GENE; CONTROLLED STUDY; GENE; GENE EXPRESSION; HEART CONDUCTION; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HYPERTROPHIC CARDIOMYOPATHY; IMMUNOBLOTTING; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; ANIMAL; DISEASE MODEL; ENZYMOLOGY; GENE INACTIVATION; GENETICS; HEART MUSCLE; HEART RATE; HEART VENTRICLE PRESSURE; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY;

ANIMALS; CARDIOMYOPATHY, HYPERTROPHIC; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENE KNOCKOUT TECHNIQUES; HEART RATE; MALE; MICE, KNOCKOUT; MYOCARDIUM; PLASMA MEMBRANE CALCIUM-TRANSPORTING ATPASES; TROPOMYOSIN; VENTRICULAR PRESSURE;

EID: 84908454186     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2014.09.025     Document Type: Article

References (96)

1. van Dorp W.G., ten Cate F.J., Vletter W.B., Dohmen H., Roelandt J. Familial prevalence of asymmetric septal hypertrophy. Eur J Cardiol 1976, 4:349-357.
2. Bjarnason I., Jonsson S., Hardarson T. Mode of inheritance of hypertrophic cardiomyopathy in Iceland. Echocardiographic study. Br Heart J 1982, 47:122-129.
3. Greaves S.C., Roche A.H., Neutze J.M., Whitlock R.M., Veale A.M. Inheritance of hypertrophic cardiomyopathy: a cross sectional and M mode echocardiographic study of 50 families. Br Heart J 1987, 58:259-266.
4. Lind J.M., Chiu C., Semsarian C. Genetic basis of hypertrophic cardiomyopathy. Expert Rev Cardiovasc Ther 2006, 4:927-934.
5. Lowey S. Functional consequences of mutations in the myosin heavy chain at sites implicated in familial hypertrophic cardiomyopathy. Trends Cardiovasc Med 2002, 12:348-354.
6. Morimoto S. Sarcomeric proteins and inherited cardiomyopathies. Cardiovasc Res 2008, 77:659-666.
7. Debold E.P., Schmitt J.P., Patlak J.B., Beck S.E., Moore J.R., Seidman J.G., et al. Hypertrophic and dilated cardiomyopathy mutations differentially affect the molecular force generation of mouse alpha-cardiac myosin in the laser trap assay. Am J Physiol Heart Circ Physiol 2007, 293:H284-H291.
8. Olivotto I., Maron B.J., Appelbaum E., Harrigan C.J., Salton C., Gibson C.M., et al. Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol 2010, 106:261-267.
9. Moore J.R., Leinwand L., Warshaw D.M. Understanding cardiomyopathy phenotypes based on the functional impact of mutations in the myosin motor. Circ Res 2012, 111:375-385.
10. Sommese R.F., Sung J., Nag S., Sutton S., Deacon J.C., Choe E., et al. Molecular consequences of the R453C hypertrophic cardiomyopathy mutation on human β-cardiac myosin motor function. Proc Natl Acad Sci U S A 2013, 110:12607-12612.
11. Bottinelli R., Coviello D.A., Redwood C.S., Pellegrino M.A., Maron B.J., Spirito P., et al. A mutant tropomyosin that causes hypertrophic cardiomyopathy is expressed in vivo and associated with an increased calcium sensitivity. Circ Res 1998, 82:106-115.
12. Spindler M., Saupe K.W., Christe M.E., Sweeney H.L., Seidman C.E., Seidman J.G., et al. Diastolic dysfunction and altered energetics in the alphaMHC403/+mouse model of familial hypertrophic cardiomyopathy. J Clin Invest 1998, 101:1775-1783.
13. Gao W.D., Pérez N.G., Seidman C.E., Seidman J.G., Marbán E. Altered cardiac excitation-contraction coupling in mutant mice with familial hypertrophic cardiomyopathy. J Clin Invest 1999, 103:661-666.
14. Karibe A., Tobacman L.S., Strand J., Butters C., Back N., Bachinski L.L., et al. Hypertrophic cardiomyopathy caused by a novel alpha-tropomyosin mutation (V95A) is associated with mild cardiac phenotype, abnormal calcium binding to troponin, abnormal myosin cycling, and poor prognosis. Circulation 2001, 103:65-71.
15. Force T., Bonow R.O., Houser S.R., Solaro R.J., Hershberger R.E., Adhikari B., et al. Research priorities in hypertrophic cardiomyopathy: report of a working group of the National Heart, Lung, and Blood Institute. Circulation 2010, 122:1130-1133.
16. Hada Y., Sakamoto T., Amano K., Yamaguchi T., Takenaka K., Takahashi H., et al. Prevalence of hypertrophic cardiomyopathy in a population of adult Japanese workers as detected by echocardiographic screening. Am J Cardiol 1987, 59:183-184.
17. Maron B.J., Gardin J.M., Flack J.M., Gidding S.S., Kurosaki T.T., Bild D.E. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA study. Coronary artery risk development in (young) adults. Circulation 1995, 92:785-789.
18. Maron B.J., Doerer J.J., Haas T.S., Tierney D.M., Mueller F.O. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation 2009, 119:1085-1092.
19. Hammes A., Oberdorf-Maass S., Rother T., Nething K., Gollnick F., Linz K.W., et al. Overexpression of the sarcolemmal calcium pump in the myocardium of transgenic rats. Circ Res 1998, 83:877-888.
20. Strehler E.E. Plasma membrane calcium ATPases as novel candidates for therapeutic agent development. J Pharm Pharm Sci 2013, 16:190-206.
21. Brandt P., Neve R.L., Kammesheidt A., Rhoads R.E., Vanaman T.C. Analysis of the tissue-specific distribution of mRNAs encoding the plasma membrane calcium-pumping ATPases and characterization of an alternately spliced form of PMCA4 at the cDNA and genomic levels. J Biol Chem 1992, 267:4376-4385.
22. Keeton T.P., Burk S.E., Shull G.E. Alternative splicing of exons encoding the calmodulin-binding domains and C termini of plasma membrane Ca(2+)-ATPase isoforms 1, 2, 3, and 4. J Biol Chem 1993, 268:2740-2748.
23. Santiago-García J., Mas-Oliva J., Saavedra D., Zarain-Herzberg A. Analysis of mRNA expression and cloning of a novel plasma membrane Ca(2+)-ATPase splice variant in human heart. Mol Cell Biochem 1996, 155:173-182.
24. Williams J.C., Armesilla A.L., Mohamed T.M., Hagarty C.L., McIntyre F.H., Schomburg S., et al. The sarcolemmal calcium pump, alpha-1 syntrophin, and neuronal nitric-oxide synthase are parts of a macromolecular protein complex. J Biol Chem 2006, 281:23341-23348.
25. Oceandy D., Cartwright E.J., Emerson M., Prehar S., Baudoin F.M., Zi M., et al. Neuronal nitric oxide synthase signaling in the heart is regulated by the sarcolemmal calcium pump 4b. Circulation 2007, 115:483-492.
26. Oceandy D., Mohamed T.M., Cartwright E.J., Neyses L. Local signals with global impacts and clinical implications: lessons from the plasma membrane calcium pump (PMCA4). Biochim Biophys Acta 2011, 1813:974-978.
27. Schuh K., Uldrijan S., Telkamp M., Rothlein N., Neyses L. The plasmamembrane calmodulin-dependent calcium pump: a major regulator of nitric oxide synthase I. J Cell Biol 2001, 155:201-205.
28. Buch M.H., Pickard A., Rodriguez A., Gillies S., Maass A.H., Emerson M., et al. The sarcolemmal calcium pump inhibits the calcineurin/nuclear factor of activated T-cell pathway via interaction with the calcineurin A catalytic subunit. J Biol Chem 2005, 280:29479-29487.
29. Piuhola J., Hammes A., Schuh K., Neyses L., Vuolteenaho O., Ruskoaho H. Overexpression of sarcolemmal calcium pump attenuates induction of cardiac gene expression in response to ET-1. Am J Physiol Regul Integr Comp Physiol 2001, 281:R699-R705.
30. 2+-ATPase isoform 4 antagonizes cardiac hypertrophy in association with calcineurin inhibition in rodents. J Clin Invest 2009, 119:976-985.
31. Prabhakar R., Boivin G.P., Grupp I.L., Hoit B., Arteaga G., Solaro R.J., et al. A familial hypertrophic cardiomyopathy alpha-tropomyosin mutation causes severe cardiac hypertrophy and death in mice. J Mol Cell Cardiol 2001, 33:1815-1828.
32. 2+-ATPase (PMCA) 1 and 4 indicates a major housekeeping function for PMCA1 and a critical role in hyperactivated sperm motility and male fertility for PMCA4. J Biol Chem 2004, 279:33742-33750.
33. Kranias E.G., Bers D.M. Calcium and cardiomyopathies. Subcell Biochem 2007, 45:523-537.
34. Marks A.R. Calcium cycling proteins and heart failure: mechanisms and therapeutics. J Clin Invest 2013, 123:46-52.
35. MacLennan D.H., Kranias E.G. Phospholamban: a crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol 2003, 4:566-577.
36. Al Moamen N.J., Prasad V., Bodi I., Miller M.L., Neiman M.L., Lasko V.M., et al. Loss of the AE3 anion exchanger in a hypertrophic cardiomyopathy model causes rapid decompensation and heart failure. J Mol Cell Cardiol 2011, 50:137-146.
37. Molkentin J.D., Lu J.R., Antos C.L., Markham B., Richardson J., Robbins J., et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998, 93:215-228.
38. Yamada M., Ikeda Y., Yano M., Yoshimura K., Nishino S., Aoyama H., et al. Inhibition of protein phosphatase 1 by inhibitor-2 gene delivery ameliorates heart failure progression in genetic cardiomyopathy. FASEB J 2006, 20:1197-1199.
39. Gergs U., Boknik P., Buchwalow I., Fabritz L., Matus M., Justus I., et al. Overexpression of the catalytic subunit of protein phosphatase 2A impairs cardiac function. J Biol Chem 2004, 279:40827-40834.
40. Tolstykh T., Lee J., Vafai S., Stock J.B. Carboxyl methylation regulates phosphoprotein phosphatase 2A by controlling the association of regulatory B subunits. EMBO J 2000, 19:5682-5691.
41. Wu J., Tolstykh T., Lee J., Boyd K., Stock J.B., Broach J.R. Carboxyl methylation of the phosphoprotein phosphatase 2A catalytic subunit promotes its functional association with regulatory subunits in vivo. EMBO J 2000, 19:5672-5681.
42. DeGrande S.T., Little S.C., Nixon D.J., Wright P., Snyder J., Dun W., et al. Molecular mechanisms underlying cardiac protein phosphatase 2A regulation in heart. J Biol Chem 2013, 288:1032-1046.
43. Chandra M., Tschirgi M.L., Tardiff J.C. Increase in tension-dependent ATP consumption induced by cardiac troponin T mutation. Am J Physiol Heart Circ Physiol 2005, 289:H2112-H2119.
44. 2+]i. J Biomech 2007, 40:2044-2052.
45. Nagendran J., Waller T.J., Dyck J.R.A.M.P.K. Signalling and the control of substrate use in the heart. Mol Cell Endocrinol 2013, 366:180-193.
46. Sussman M.A., Veölkers M., Fischer K., Bailey B., Cottage C.T., Din S., et al. Myocardial AKT: the omnipresent nexus. Physiol Rev 2011, 91:1023-1070.
47. He L., Kim T., Long Q., Liu J., Wang P., Zhou Y., et al. Carnitine palmitoyltransferase-1b deficiency aggravates pressure overload-induced cardiac hypertrophy caused by lipotoxicity. Circulation 2012, 126:1705-1716.
48. Domenighetti A.A., Danes V.R., Curl C.L., Favaloro J.M., Proietto J., Delbridge L.M. Targeted GLUT-4 deficiency in the heart induces cardiomyocyte hypertrophy and impaired contractility linked with Ca(2+) and proton flux dysregulation. J Mol Cell Cardiol 2010, 48:663-672.
49. Carnicer R., Crabtree M.J., Sivakumaran V., Casadei B., Kass D.A. Nitric oxide synthases in heart failure. Antioxid Redox Signal 2013, 18:1078-1099.
50. Ziolo M.T., Kohr M.J., Wang H. Nitric oxide signaling and the regulation of myocardial function. J Mol Cell Cardiol 2008, 45:625-632.
51. Sechi A.S., Wehland J. ENA/VASP proteins: multifunctional regulators of actin cytoskeleton dynamics. Front Biosci 2004, 9:1294-1310.
52. Gambaryan S., Hauser W., Kobsar A., Glazova M., Walter U. Distribution, cellular localization, and postnatal development of VASP and Mena expression in mouse tissues. Histochem Cell Biol 2001, 116:535-543.
53. Benz P.M., Merkel C.J., Offner K., Abeßer M., Ullrich M., Fischer T., et al. Mena/VASP and αII-Spectrin complexes regulate cytoplasmic actin networks in cardiomyocytes and protect from conduction abnormalities and dilated cardiomyopathy. Cell Commun Sign 2013, 11:56.
54. Eigenthaler M., Engelhardt S., Schinke B., Kobsar A., Schmitteckert E., Gambaryan S., et al. Disruption of cardiac Ena-VASP protein localization in intercalated disks causes dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2003, 285:H2471-H2481.
55. Butt E., Abel K., Krieger M., Palm D., Hoppe V., Hoppe J., et al. cAMP- and cGMP-dependent protein kinase phosphorylation sites of the focal adhesion vasodilator-stimulated phosphoprotein (VASP) in vitro and in intact human platelets. J Biol Chem 1994, 269:14509-14517.
56. Harbeck B., Hüttelmaier S., Schluter K., Jockusch B.M., Illenberger S. Phosphorylation of the vasodilator-stimulated phosphoprotein regulates its interaction with actin. J Biol Chem 2000, 275:30817-30825.
57. Oelze M., Mollnau H., Hoffmann N., Warnholtz A., Bodenschatz M., Smolenski A., et al. Vasodilator-stimulated phosphoprotein serine 239 phosphorylation as a sensitive monitor of defective nitric oxide/cGMP signaling and endothelial dysfunction. Circ Res 2000, 87:999-1005.
58. Sheikh F., Raskin A., Chu P.H., Lange S., Domenighetti A.A., Zheng M., et al. An FHL1-containing complex within the cardiomyocyte sarcomere mediates hypertrophic biomechanical stress responses in mice. J Clin Invest 2008, 118:3870-3880.
59. Hojayev B., Rothermel B.A., Gillette T.G., Hill J.A. FHL2 binds calcineurin and represses pathological cardiac growth. Mol Cell Biol 2012, 32:4025-4034.
60. Chen S.N., Czernuszewicz G., Tan Y., Lombardi R., Jin J., Willerson J.T., et al. Human molecular genetic and functional studies identify TRIM63, encoding muscle RING finger protein 1, as a novel gene for human hypertrophic cardiomyopathy. Circ Res 2012, 111:907-919.
61. Witt C.C., Witt S.H., Lerche S., Labeit D., Back W., Labeit S. Cooperative control of striated muscle mass and metabolism by MuRF1 and MuRF2. EMBO J 2008, 27:350-360.
62. Mikhailov A.T., Torrado M. The enigmatic role of the ankyrin repeat domain 1 gene in heart development and disease. Int J Dev Biol 2008, 52:811-821.
63. Miller M.K., Bang M.L., Witt C.C., Labeit D., Trombitas C., Watanabe K., et al. The muscle ankyrin repeat proteins: CARP, ankrd2/Arpp and DARP as a family of titin filament-based stress response molecules. J Mol Biol 2003, 333:951-964.
64. Linke W.A. Sense and stretchability: the role of titin and titin-associated proteins in myocardial stress-sensing and mechanical dysfunction. Cardiovasc Res 2008, 77:637-648.
65. Fukuda N., Terui T., Ishiwata S., Kurihara S. Titin-based regulations of diastolic and systolic functions of mammalian cardiac muscle. J Mol Cell Cardiol 2010, 48:876-881.
66. Cazorla O., Freiburg A., Helmes M., Centner T., McNabb M., Wu Y., et al. Differential expression of cardiac titin isoforms and modulation of cellular stiffness. Circ Res 2000, 86:59-67.
67. Lorenz J.N., Robbins J. Measurement of intraventricular pressure and cardiac performance in the intact closed-chest anesthetized mouse. Am J Physiol Heart Circ Physiol 1997, 272:H1137-H1146.
68. 2+-ATPase isoform 2 (SERCA2) gene. J Biol Chem 1999, 274:2556-2562.
69. Koch S.E., Haworth K.J., Robbins N., Smith M.A., Lather N., Anjak A., et al. Age- and gender-related changes in ventricular performance in wild-type FVB/N mice as evaluated by conventional and vector velocity echocardiography imaging: a retrospective study. Ultrasound Med Biol 2013, 39:2034-2043.
70. Galderisi M. Diastolic dysfunction and diastolic heart failure: diagnostic, prognostic and therapeutic aspects. Cardiovasc Ultrasound 2005, 3:9.
71. Bella J.N., Palmieri V., Roman M.J., Liu J.E., Welty T.K., Lee E.T., et al. Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults: the Strong Heart Study. Circulation 2002, 105:1928-1933.
72. Nagueh S.F., Mikati I., Kopelen H.A., Middleton K.J., Quiñones M.A., Zoghbi W.A. Doppler estimation of left ventricular filling pressure in sinus tachycardia. A new application of tissue Doppler imaging. Circulation 1998, 98:1644-1650.
73. 2+ transport activities in cardiac hypertrophy caused by pressure overload. Am J Physiol 1989, 257:H349-H356.
74. Louch W.E., Hougen K., Mork H.K., Swift F., Aronsen J.M., Sjaastad I., et al. Sodium accumulation promotes diastolic dysfunction in end-stage heart failure following Serca2 knockout. J Physiol 2010, 588:465-478.
75. Pena J.R., Szkudlarek A.C., Warren C.M., Heinrich L.S., Gaffin R.D., Jagatheesan G., et al. Neonatal gene transfer of Serca2a delays onset of hypertrophic remodeling and improves function in familial hypertrophic cardiomyopathy. J Mol Cell Cardiol 2010, 49:993-1002.
76. Gaffin R.D., Pena J.R., Alves M.S., Dias F.A., Chowdhury S.A., Heinrich L.S., et al. J Mol Cell Cardiol 2011, 51:812-820.
77. 2+ as a therapeutic target for hypertrophic cardiomyopathy with mutations in thin filament proteins. Circ Cardiovasc Genet 2014, 7:132-143.
78. Schulz E.M., Wilder T., Chowdhury S.A., Sheikh H.N., Wolska B.M., Solaro R.J., et al. Decreasing tropomyosin phosphorylation rescues tropomyosin-induced familial hypertrophic cardiomyopathy. J Biol Chem 2013, 288:28925-28935.
79. 2+ channel antagonist inhibits hypertrophic signaling without reducing cardiac contractility. Circ Res 2012, 110:669-674.
80. Semsarian C., Ahmad I., Giewat M., Georgakopoulos D., Schmitt J.P., McConnell B.K., et al. The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest 2002, 109:1013-1020.
81. Lan F., Lee A.S., Liang P., Sanchez-Freire V., Nguyen P.K., Wang L., et al. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell 2013, 12:101-113.
82. Gao H., Wang F., Wang W., Makarewich C.A., Zhang H., Kubo H., et al. Ca(2+) influx through L-type Ca(2+) channels and transient receptor potential channels activates pathological hypertrophy signaling. J Mol Cell Cardiol 2012, 53:657-667.
83. Lopaschuk G.D., Ussher J.R., Folmes C.D., Jaswal J.S., Stanley W.C. Myocardial fatty acid metabolism in health and disease. Physiol Rev 2010, 90:207-258.
84. Haynie K., Vandanmagsar B., Wicks S., Zhang J., Mynatt R. Inhibition of carnitine palymitoyltransferase1b induces cardiac hypertrophy and mortality in mice. Diabetes Obes Metab 2014, 16:757-760.
85. Aerni-Flessner L., Abi-Jaoude M., Koenig A., Payne M., Hruz P.W. GLUT4, GLUT1, and GLUT8 are the dominant GLUT transcripts expressed in the murine left ventricle. Cardiovasc Diabetol 2012, 11:63.
86. Rajan S., Williams S.S., Jagatheesan G., Ahmed R.P., Fuller-Bicer G., Schwartz A., et al. Microarray analysis of gene expression during early stages of mild and severe cardiac hypertrophy. Physiol Genomics 2006, 27:309-317.
87. Crilley J.G., Boehm E.A., Blair E., Rajagopalan B., Blamire A.M., et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol 2003, 41:1776-1782.
88. Ferrantini C., Belus A., Piroddi N., Scellini B., Tesi C., Poggesi C. Mechanical and energetic consequences of HCM-causing mutations. J Cardiovasc Transl Res 2009, 2:441-451.
89. Takimoto E. Cyclic GMP-dependent signaling in cardiac myocytes. Circ J 2012, 76:1819-1825.
90. Krüger M., Kötter S., Grützner A., Lang P., Andresen C., Redfield M.M., et al. Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. Circ Res 2009, 104:87-94.
91. Feron O., Belhassen L., Kobzik L., Smith T.W., Kelly R.A., Michel T. Endothelial nitric oxide synthase targeting to caveolae. Specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells. J Biol Chem 1996, 271:22810-22814.
92. Lima B., Forrester M.T., Hess D.T., Stamler J.S. S-nitrosylation in cardiovascular signaling. Circ Res 2010, 106:633-646.
93. Gotsman M.S., Lewis B.S. Left ventricular volumes and compliance in hypertrophic cardiomyopathy. Chest 1974, 66:498-505.
94. Mohamed T.M., Oceandy D., Zi M., Prehar S., Alatwi N., Wang Y., et al. Plasma membrane calcium pump (PMCA4)-neuronal nitric-oxide synthase complex regulates cardiac contractility through modulation of a compartmentalized cyclic nucleotide microdomain. J Biol Chem 2011, 286:41520-41529.
95. 2+ ATPase 4 is required for sperm motility and male fertility. J Biol Chem 2004, 279:28220-28226.
96. Williams R.S., Bishop T. Selectivity of dobutamine for adrenergic receptor subtypes: in vitro analysis by radioligand binding. J Clin Invest 1981, 67:1703-1711.